Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence.

Published byはすな ますはら Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence."— Presentation transcript:

1 Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus
Figure 2 | Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus. a | Subtly abnormal irregular mucosa seen in the lower half of the white-light endoscopy image in a patient with Barrett oesophagus. b | Autofluorescence endoscopy image revealing a purple patch of abnormal Barrett mucosa, raising suspicion of dysplasia. c | High-magnification narrow-band imaging confirming a dysplastic area with abnormal vasculature and destroyed pits. Reproduced with permission from Macmillan Publishers Ltd © Mannath, J. & Ragunath, K. Nat. Rev. Gastroenterol. Hepatol. 13, 720–730 (2016). Reproduced with permission from Macmillan Publishers Ltd © Mannath, J. & Ragunath, K. Nat. Rev. Gastroenterol. Hepatol. 13, 720–730 (2016). Hoffman, A. et al. (2017) A guide to multimodal endoscopy imaging for gastrointestinal malignancy — an early indicator Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence."

Similar presentations

Figure 2 Electromechanical properties of OIHPs

Figure 2 Electromechanical properties of OIHPs
Figure 3 Low-grade inflammation in FGID

Figure 3 Low-grade inflammation in FGID
Figure 2 Endoscopic imaging of intestinal villi

Figure 2 Endoscopic imaging of intestinal villi
Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 8 Implanted devices for the management of heart failure

Figure 8 Implanted devices for the management of heart failure
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 The microbiome–gut–brain axis

Figure 2 The microbiome–gut–brain axis
Figure 3 The T-cell cytokine tree in IBD

Figure 3 The T-cell cytokine tree in IBD
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Molecular endoscopy for targeted imaging in the digestive tract

Molecular endoscopy for targeted imaging in the digestive tract
Figure 3 Algorithm from working group describing

Figure 3 Algorithm from working group describing
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Combination therapy for HCC

Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Similar presentations

Ads by Google